Changes to Board
Oxford
BioMedica plc (LSE:OXB) ("BioMedica") announced
today that Mr. Peter Nolan is to join the Board as an executive
director as Senior Vice President for Commercial Development.
In addition, Dr. Paul Durrands has resigned from the Board
of Oxford BioMedica in order to pursue other opportunities
in the biotech sector.
Peter
Nolan has been a senior member of the Company since its foundation,
and is a director of the UK BioIndustry Association. Prior
to joining BioMedica, he was head of the Biotechnology Unit
at the UK Department of Trade & Industry. At BioMedica,
he has overall responsibility for the Company's patent portfolio,
which was enhanced substantially last year with several broad
patents being issued in the USA and Europe. He is also in
charge of all strategic in-licensing and technology acquisition
activities. In his new role he will add to his duties the
analysis of merger and acquisition opportunities.
Commenting
on the changes to the Board, the CEO of Oxford BioMedica,
Professor Alan Kingsman said: "We are delighted to
welcome Peter to the Board of Oxford BioMedica. His broad
experience in intellectual property management and technology
transfer will strengthen the Board. We wish Paul Durrands
well in his new ventures and we thank him for his contributions
to the Company".
-Ends-
|
Return to the News
| Notes
| 1. |
Oxford
BioMedica plc
Established
in 1995, the Company specialises in the application
of gene-based technology to the development of novel
therapeutics. Its three principal activities are in
the fields of gene therapy, immunotherapy and genomics,
and its principal therapeutic areas are in cancer and
neurodegenerative diseases. Oxford BioMedica plc was
floated on the Alternative Investment Market of the
London Stock Exchange in December 1996, and was promoted
to the United Kingdom Listing Authority Official List
in April 2001 following a successful £35.5 million
fund-raising.
Oxford
BioMedica is headquartered in Oxford, UK and has operating
centres in Oxford and San Diego, USA
Currently
Oxford BioMedica has corporate collaborations with Aventis,
IDM, Nycomed Amersham, Valentis, Virbac and Wyeth. BioMedica
has two products in Phase I/II clinical trials: MetXia®
for late-stage breast cancer, and TroVax®
for late-stage colorectal cancer. |
|
| For
further information please contact: |
|
|
Oxford BioMedica plc
Professor Alan
Kingsman, Chief Executive |
Tel: +44 (0)1865 783 000 |
| City/Financial
Enquiries
Melanie Toyne Sewell/Fiona Noblet
Financial Dynamics |
Tel: +44 (0)20 7831 3113
|
| Scientific/Trade
Enquiries
Chris
Gardner, HCC De Facto Group |
Tel:
+44 (0)20 7496 3300 |
|
|
|
Top
of page
Website by College Hill - Life Sciences |
| |
|
|
